

Does Obesity Affect the Dosage Requirements For Oral Benzodiazepines or Opioids?

Introduction

Drug pharmacokinetics may be altered in an obese individual but there are few cases where these changes will be clinically significant. In this review, the mechanisms by which obesity can affect pharmacokinetic parameters will be discussed, followed by specific data for opioids and benzodiazepines. Opioids and benzodiazepines are chosen for review as there is a misperception that obese individuals will require higher oral doses of these drugs.

General principles

Drug **absorption** is not impacted by obesity (1). It has been hypothesized that since obesity increases splanchnic blood flow, the subsequent increase in perfusion of the small intestine where most drugs are absorbed could result in higher drug bioavailability. However, the effect of this, if it does occur, is not clinically significant (2-5).

Distribution of drugs may be altered in obesity. A higher proportion of a drug could distribute into adipose tissue in an obese individual, significantly increasing the **volume of distribution (V_D)**. This would only affect lipophilic drugs. The consequences of an increased V_D are (6,7):

- delayed onset of action for a drug
- drug accumulation in adipose tissue, which will slowly release into plasma
- prolonged half-life, leading to a longer time to steady-state

Clinically, this is only important when a rapid response from a lipophilic drug is needed (e.g. an intravenous loading dose of lorazepam for status epilepticus). Dosing in this situation should be based on the patient's total body weight (TBW). Otherwise, with chronic oral dosing, plasma concentrations for a given dose will be the same in obese vs. non-obese individuals once steady-state has been reached — it may just take longer to reach steady-state in the obese individual.

Metabolism, specifically liver metabolism, is variably affected by obesity. CYP 2E1, 1A2, 2C9, and possibly 2C19 and 2D6 are induced; CYP 3A4 is inhibited (8). Phase II enzymes (e.g. UGTs) also may be induced. However, these changes are usually insignificant, with a few exceptions. Triazolam (3A4 substrate), showed significantly higher plasma levels in obese individuals due to reduced clearance (9). Lorazepam (UGT substrate) showed increased clearance, but this effect was offset by accumulation of the drug in fatty tissue (9).

Elimination may be increased in obesity because of increased glomerular filtration rate (GFR), increased renal tubular secretion, and decreased tubular reabsorption (1). However, other comorbidities in obesity will often offset the increased excretion and the overall effect is unlikely to be relevant except for drugs with a narrow therapeutic window that are primarily eliminated renally (10). For purposes of drug dosing in an obese patient, it is recommended to use lean body weight (LBW) to estimate GFR (11).

Oral Opioid Dosing in Obesity

Analgesic response to oral (and parenteral) opioids does not appear to be affected by weight according to recent studies (7,12-14). It has also been demonstrated that morphine plasma concentrations do not correlate with analgesic effect (15). Thus, oral opioids should be dosed without regard to weight, following the general recommendation of starting low, then titrating to effect. Also, consider that obesity may increase the risk of sleep apnea and respiratory depression associated with opioids (16). Table 1 summarizes theoretical and actual clinical data for select opioids.

Table 1: Opioid Pharmacokinetic Changes Associated with Obesity

Opioid	Hydrophilic (●) or Lipophilic (V)	Theoretical changes in obesity	Studied Clinical changes in obesity
Morphine	● ●	- Increased clearance if eGFR high, leading to lower duration of analgesia; increased liver metabolism via. UGT2B7 (17)	- Clinical changes not well studied - Increases in clearance likely only significant in morbidly obese (18)
Oxycodone	● ●	- Increased clearance if eGFR high, leading to lower duration of analgesia	- Weight did not impact dosing needs in cancer patients (19)
Hydromorphone	● / V (intermediate)	- Increased V_D ; increased liver metabolism via glucuronidation	- Kinetic changes not studied - No correlation between weight and analgesia (20,21)
Methadone	V V	- Increased accumulation and half-life potential due to lipophilicity; magnitude unstudied	- Weight did not influence clearance, but did increase V_D and accumulation potential (22,23) - Methadone displays high interpatient variability, unrelated to weight (24,25)
Fentanyl (transdermal)	V V V	- High lipophilicity indicates increased accumulation and half-life, and possible increased steady-state concentrations. - Initial analgesic response may be delayed	- Changes in transdermal kinetics in obesity have not been studied - IV dosing based on TBW may lead to over-dosage (26)

Oral Benzodiazepine Dosing in Obesity

Most benzodiazepines are lipophilic, which theoretically means increased half-lives, accumulation potential, and possible delayed onset of action in obesity. In general though, these changes are small and no dosing changes are required for obese individuals. As with opioids, benzodiazepine doses should be started low and titrated to effect, regardless of weight. Table 2 summarizes clinical data on obesity-related kinetic changes in benzodiazepine therapy.

Table 2: Benzodiazepine Pharmacokinetic Changes Associated with Obesity

Benzodiazepine	Theoretical and Observed Data
Alprazolam (25)	<ul style="list-style-type: none"> - Half-life increased from 11h to 22h in obesity - Final plasma concentrations the same in obese and non-obese at steady-state - Metabolism and clearance unchanged
Clonazepam	<ul style="list-style-type: none"> - No kinetic studies available - Likely similar to other benzodiazepines; increased half-life, similar area under the curve (AUC) at steady-state
Diazepam (26)	<ul style="list-style-type: none"> - Half-life markedly prolonged from 56h to 130h in obesity - AUC at steady-state is same in obese and non-obese individuals - Clearance unchanged
Lorazepam (27)	<ul style="list-style-type: none"> - Increased V_D leading to longer half-life - Clearance is increased, but offset by increased V_D and accumulation - Net effect is only a slightly prolonged half-life in obesity
Triazolam	<ul style="list-style-type: none"> - Half-life increased from 2.6h to 4.1h (25) - AUC was slightly greater in obesity due to decreased clearance (3A4 inhibition) (28)

Summary

For oral benzodiazepines and opioids, obesity does not affect dosage requirements. In some cases, obesity will increase half-lives, potential for accumulation and delay onset of action, but steady-state concentrations and overall clinical effect are unchanged.

If you have any questions about this information or would like to discuss a specific situation involving opioid or benzodiazepine dosing, please feel free to contact the medication information consultants at medSask: telephone 306-966-6340 (Saskatoon) or 1-800-667-3425 (anywhere in Saskatchewan) or email druginfo@usask.ca.

Prepared by T. Damm, BSP, K. Jensen BSP, MSc and C. Bell BSP
medSask, November 2017

References:

1. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. *Clin Pharmacokinet.* 2010; 49(2): 71-87.
2. Greenblatt DJ, Abernathy DR, Locniska A, et al. Effect of age, gender and obesity on midazolam kinetics. *Anesthesiology.* 1984;61:27-35.
3. Bowman SL, Hudson SA, Simpson G, et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. *Br J Clin Pharmacol.* 1986;21:529-532.
4. Flechner SM, Kilbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. *Transplantation.* 1989;47:806-810.

5. Cheymol G, Weissenburger J, Poirier JM, et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. *Br J Clin Pharmacol.* 1995;39:684-687.
6. Drug dosing in special populations: renal and hepatic disease, dialysis, heart failure, obesity, and drug interactions. In: Bauer LA. ed. *Applied Clinical Pharmacokinetics*, 3e New York, NY: McGraw-Hill; <http://accesspharmacy.mhmedical.com/content.aspx?bookid=1374§ionid=74719619>. Accessed August 3, 2017.
7. Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. *J Pediatr Pharmacol Ther.* 2010; 15(2):94-109.
8. Brill MJ, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. *Clin Pharmacokinet.* 2012;51(5):277-304.
9. Lau S, Cheung LK, Chow D. Application of pharmaco-kinetics to specific populations: geriatric, obese, and pediatric patients. In: Shargel L, Yu AC. eds. *Applied Biopharmaceutics & Pharmacokinetics*, 7e New York, NY: McGraw-Hill; . <http://accesspharmacy.mhmedical.com/content.aspx?bookid=1592§ionid=100675238>. Accessed August 03, 2017.
10. Wuerzner G, Bochud M, Giusti V, et al. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences. *Obes Facts* 2011;4:238–243.
11. Manjunath P. Estimating the glomerular filtration rate in obese adult patients for drug dosing. *Adv Chronic Kidney Dis.* 2010; 17(5): 353-e62.
12. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. *Intensive Care Med.* 2004;30:18–31.
13. Naqvi A, Ebloughdady I, Marquez-Lara A, et al. Opioid requirements in obese patients following a minimally invasive transforaminal lumbar interbody fusion. Abstract Presentation. [Accessed Jul 2017] Available at: <http://www.smss.org/abstract/opioid-requirements-obese-patients-following-minimally-invasive-transforaminal-lumbar>
14. Patanwala AE, Holmes KL, Erstad BL. Analgesic response to morphine in obese and morbidly obese patients in the emergency department. *Emerg Med J.* 2014;31:139-142.
15. Hammoud HA, Aymard G, Lechat P, et al. Relationships between plasma concentrations of morphine, morphine-3-glucuronide, morphine-6-glucuronide, and intravenous morphine titration outcomes in the postoperative period. *Fundam Clin Pharmacol.* 2011; 25(4): 518-527.
16. Schumacher M. Pain Management for the obese sleep apnea patient. UCSF Dept of Anesthesia and Perioperative Care. Available at: <http://www.ucsfmcme.com/2012/slides/MAN12001/Talks/6Schumacher.pdf>.
17. Lloret-Linares C, Declèves X, Oppert JM, et al. Pharmacology of morphine in obese patients: clinical implications. *Clin Pharmacokin.* 2009; 48(10): 635-51.
18. Lloret-Linares C, Miyauchi E, Luo H, et al. Oral morphine pharmacokinetics in obesity: the role of p-glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 jejunal contents and obesity-associated biomarkers. *Mol Pharm.* 2016; 13(3): 766-773.
19. Andreassen TN, Klepstad P, Davies A, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. *Eur J Clin Pharmacol.* 2011;67(5):493-506.
20. Xia S, Chew E, Choe D, et al. No correlation between body size and hydromorphone analgesia in obese patients in ED. *Am J Emerg Med.* 2015;33(10):1522-1523
21. Xia, S, Choe D, Hernandez L, et al. Does initial hydromorphone relieve pain best if dosing is fixed or weight based? *Ann Emerg Med.* 2014 Jun;63(6):692-8.e4.
22. Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. *Br J Clin Pharmacol.* 1997;44(4):325-334.
23. Rostami-Hodjegan A, Wolff K, Hay AW, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. *Br J Clin Pharmacol.* 1999;48(1):43-52.
24. Shibutani K, Inchiosa MA Jr., Sawada K, et al. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. *Br J Anaesth.* 2005;95(3):377-83.
25. Abernethy DR, Greenblatt DJ. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. *Clin Pharmacokinet.* 1984;9(2):177-83.
26. Abernethy DR, GreenblattDJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. *J Clin Pharmacol.* 1983; 23: 369-376
27. Cheymol, G. Clinical pharmacokinetics of drugs in obesity. *Clin Pharmacokinet.* 1993; 25(2): 103-114.
28. Derry C, Kroboth P, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. *J Clin Psychopharmacol.* 1995; 15(3): 197-205.